Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes

Background: Decreased insulin clearance could be a relatively upstream abnormality in obesity, metabolic syndrome, and nonalcoholic fatty liver disease. Previous studies have shown that sodium-glucose cotransporter 2 inhibitor (SGLT2i) increases insulin–C-peptide ratio, a marker of insulin clearance...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Motonori, Tamura, Yoshifumi, Kaga, Hideyoshi, Yamasaki, Nozomu, Kiya, Mai, Kadowaki, Satoshi, Sugimoto, Daisuke, Funayama, Takashi, Someya, Yuki, Kakehi, Saori, Nojiri, Shuko, Satoh, Hiroaki, Kawamori, Ryuzo, Watada, Hirotaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472728/
https://www.ncbi.nlm.nih.gov/pubmed/34572340
http://dx.doi.org/10.3390/biomedicines9091154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472728/
https://www.ncbi.nlm.nih.gov/pubmed/34572340
http://dx.doi.org/10.3390/biomedicines9091154

Ejemplares similares